{
    "clinical_study": {
        "@rank": "52041", 
        "acronym": "AL3vs5", 
        "arm_group": [
            {
                "arm_group_label": "AL3days", 
                "arm_group_type": "Active Comparator", 
                "description": "Artemether-lumefantrine 3 days"
            }, 
            {
                "arm_group_label": "AL5days", 
                "arm_group_type": "Experimental", 
                "description": "Artemether-lumefantrine 5 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days\n      treatment. Patients will be randomised in blocks of ten to one of the two treatment arms.\n      The standard regimen is twice daily for three days with a delay of at least eight hours\n      between the first and second doses. A single of primaquine will be given to all patients on\n      the first day of treatment for gametocytocidal activity. The initial treatment will be given\n      under supervision, all other subsequent doses will be given to the patient to the taken at\n      home. Patients will be followed up for nine visits over forty two days."
        }, 
        "brief_title": "Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Plasmodium Falciparum Infection", 
        "detailed_description": {
            "textblock": "-  The study will be conducted in 6 village health centres in the Mon and Kayin states\n\n        -  The patient or parent/guardian (in case of minor or under aged)  must personally sign\n           and date the latest approved version of the informed consent form before any study\n           specific procedures are performed\n\n        -  A case record form will be completed for each patient documenting symptoms prior to\n           clinic attendance, concomitant illness, drug history. Height, weight, vital signs and\n           physical examination findings will be recorded.\n\n        -  At enrolment (D0) all patients will have the following samples taken:\n\n             -  Repeat parasite count (thick and thin films). Treatment should be started without\n                waiting for the result.\n\n             -  Filter paper blood blots (3 dots on Whatman 3MM filter paper approx 180-300 \u00b5L\n                blood) for parasite genotyping (MSP1, MSP2, GLURP in case of recurrence during\n                follow-up)\n\n             -  Haemoglobin\n\n        -  Laboratory procedures\n\n             -  Slide microscopy: Thick and thin blood films stained with Giemsa will be read and\n                counts expressed as the number of parasites per 500 white blood cells\n\n             -  Molecular studies: The samples will be used to detect asexual parasites (blood\n                smear, sensitive PCR), parasite population structure (Sequenom genotyping and\n                sequencing), gametocytes (microscopy, mRNA). The samples will be stored in a cool\n                box and kept maximum 5 days in the field and will be transported to the local\n                laboratory for processing. Plasma and buffy coat will be separated, frozen and\n                stored. The frozen packed red cells will be transported to the molecular\n                laboratory at MORU, Bangkok, Thailand, for sample processing (DNA extraction or\n                RNA isolation, quantitative PCRs)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 6 year\n\n          2. Symptomatic malaria infection, i.e. history of fever or presence of fever >37.5\u00b0C\n\n          3. Microscopic confirmation of asexual stages of P. falciparum (may be mixed with\n             non-falciparum species) with parasitaemia PFT\u22655/500 WBC\n\n          4. Written informed consent given to participate in the trial\n\n        Exclusion Criteria:\n\n          1. Pregnancy or lactation (urine test for \u03b2 HCG to be performed on any woman of child\n             bearing age unless menstruating).\n\n          2. Female of 12 to 18 years of age\n\n          3. P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells\n             (175,000/\u00b5L).\n\n          4. Signs or symptoms indicative of severe malaria including:\n\n               -  Impaired consciousness (Blantyre Coma Score <5 or Glasgow Coma Scale <15)\n\n               -  Severe anaemia (Hb% <5 mg/dl)\n\n               -  Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria,\n                  bleeding from venepuncture sites\n\n               -  Respiratory distress\n\n               -  Severe jaundice\n\n               -  Haemodynamic shock\n\n          5. A full course of artemether-lumefantrine treatment in the previous 28 days\n\n          6. Known hypersensitivity to artemisinins - defined as history of erythroderma/other\n             severe cutaneous reaction, angioedema or anaphylaxis\n\n          7. History of splenectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020330", 
            "org_study_id": "MOCRU1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "AL3days", 
                "description": "One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. Participants will be advised to take the drug with milk / food.", 
                "intervention_name": "Artemether-lumefantrine 3 days", 
                "intervention_type": "Drug", 
                "other_name": "Coartem\u00ae, Novatis, Switzerland"
            }, 
            {
                "arm_group_label": "AL5days", 
                "description": "One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. Participants will be advised to take the drug with milk / food.", 
                "intervention_name": "Artemether-lumefantrine 5 days", 
                "intervention_type": "Drug", 
                "other_name": "Coartem\u00ae, Novartis, Switzerland"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Artemether", 
                "Artemisinins", 
                "Lumefantrine", 
                "Artemether-lumefantrine combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "falciparum, malaria", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "email": "frank.m.smithuis@gmail.com", 
                "last_name": "Frank Smithuis, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Yangon", 
                    "country": "Myanmar"
                }, 
                "name": "Medical Action Myanmar"
            }, 
            "investigator": [
                {
                    "last_name": "Frank Smithuis, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Nicholas Day, MBBS", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Myanmar"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar", 
        "overall_contact": {
            "email": "frank.m.smithuis@gmail.com", 
            "last_name": "Frank Smithuis, MD"
        }, 
        "overall_contact_backup": {
            "email": "phaikyeong@tropmedres.ac", 
            "last_name": "Phaik Yeong Cheah, PhD"
        }, 
        "overall_official": {
            "affiliation": "Myanmar Oxford Clinical Research Unit", 
            "last_name": "Frank Smithuis, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed by sensitive PCR on days 5 and 7 after treatment", 
            "measure": "proportion of patients with detectable parasitaemia", 
            "safety_issue": "No", 
            "time_frame": "On day 5 and day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020330"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed by sensitive PCR on D3 in the 3 day arm and D5 in the 5 day arm", 
                "measure": "Parasitaemia clearance time", 
                "safety_issue": "No", 
                "time_frame": "On day 3 and Day 5"
            }, 
            {
                "measure": "Gametocyte carriage rates", 
                "safety_issue": "No", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "Tolerability of artemether-lumefantrine will be assessed by comparing the proportion of patients with anorexia, nausea, vomiting, abdominal pain and other symptoms of administration between the intervention arm and the control arm", 
                "measure": "artemether-lumefantrine tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }, 
            {
                "description": "Comparison of effectiveness uncorrected and corrected will be assessed by PCR genotyping", 
                "measure": "Comparison of effectiveness", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "measure": "concentrations of lumefantrine", 
                "safety_issue": "No", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "Assessed by comparing hemoglobin  between baseline and after treatment at day 28", 
                "measure": "Haematological recovery rate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 28"
            }, 
            {
                "description": "Assessed by the microscopist find malaria smear positive within the follow up period", 
                "measure": "Incidence of vivax malaria relapses", 
                "safety_issue": "No", 
                "time_frame": "42 days"
            }
        ], 
        "source": "University of Oxford", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Oxford", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}